EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment

Jürgen Wasem, Yanic Heer, Eleni Karamasioti, Erwan Muros-Le Rouzic, Giuseppe Marcelli, Danilo Di Maio, Stefan Braune, Gisela Kobelt, Paul Dillon

PharmacoEconomics - Open · 2024-09 · 8 (5) · 665-678

DOI: 10.1007/s41669-024-00501-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift PharmacoEconomics - Open, online erschienen am 01.07.2024. Verfasst von Jürgen Wasem und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Economics, University of Duisburg-Essen, Essen, Germany. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Understanding the socioeconomic burden of multiple sclerosis (MS) is essential to inform policymakers and payers. Real-world studies have associated increasing costs and worsening quality of life (QoL) with disability progression. This study aims to further evaluate the impact of cognition, fatigue, upper and lower limb function (ULF, LLF) impairments, and disease progression per Expanded Disability Status Scale (EDSS) level, on costs and QoL. METHODS: This was a cross-sectional cohort study including 20,988 patients from the German NeuroTransData MS registry from 2009 to 2019. QoL analyses were based on EQ-5D-5L. Cost analyses included indirect/direct medical and non-medical costs. Eight subgroups, ranging from 439 to 1812 patients were created based on presence of measures for disease progression (EDSS), cognition (Symbol Digit Modalities Test [SDMT]), fatigue (Modified Fatigue Impact 5-Item Scale [MFIS-5]), ULF (Nine-Hole Peg Test [9HPT]), and LLF (Timed 25-Foot Walk [T25FW]). Multivariable linear regression assessed the independent effect of each test's score on QoL and costs, while adjusting for EDSS and 12 other confounders. RESULTS: Lower QoL was associated with decreasing cognition (p < 0.001), worsening ULF (p = 0.025), and increasing fatigue (p < 0.0001); however, the negative impact of LLF worsening on QoL was not statistically significant (p = 0.54). Higher costs were associated with decreasing cognition (p < 0.001), worsening of ULF (p = 0.0058) and LLF (p = 0.049), and increasing fatigue (p < 0.0001). Each 1-scale-step worsening function of SDMT, MFIS-5, 9HPT, and T25FW scores resulted in €170, €790, €330, and €520 higher costs, respectively. Modeling disability progression based on SDMT, MFIS-5, 9HPT, and T25FW scores as an interaction with EDSS strata found associations with lower QoL and higher costs at variable EDSS ranges. CONCLUSIONS: Disease progression in MS measured by 9HPT, SDMT, and MFIS-5 had a significant negative impact on QoL and broad socioeconomic costs independent of EDSS. T25FW had a significant negative association with costs. Cognition, fatigue, ULF, and LLF have stronger impact on costs and QoL in patients with higher EDSS scores. Additional determinants of MS disability status, including SDMT, MFIS-5, 9HPT, and T25FW, should be considered for assessing cost effectiveness of novel therapeutics for MS.

Autor:innen und Institutionen

  • Faculty of Economics, University of Duisburg-Essen, Essen, Germany.
  • PricewaterhouseCoopers (PwC), Zurich, Switzerland.
  • F. Hoffmann-La Roche Ltd., Basel, Switzerland. erwan.muros@roche.com.
  • F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • NeuroTransData GmbH, Neuburg an der Donau, Germany.
  • EHE International, St Moritz, Switzerland.

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Wasem, J., Heer, Y., Karamasioti, E., Muros-Le Rouzic, E., Marcelli, G., Di Maio, D., Braune, S., Kobelt, G., & Dillon, P. (2024). Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment. PharmacoEconomics - Open, 8(5), 665-678. https://doi.org/10.1007/s41669-024-00501-x

Vancouver

Wasem J, Heer Y, Karamasioti E, Muros-Le Rouzic E, Marcelli G, Di Maio D, et al. Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment. PharmacoEconomics - Open. 2024;8(5):665-678. doi:10.1007/s41669-024-00501-x

BibTeX
@article{Wasem2024,
  author = {Wasem, Jürgen and Heer, Yanic and Karamasioti, Eleni and Muros-Le Rouzic, Erwan and Marcelli, Giuseppe and Di Maio, Danilo and Braune, Stefan and Kobelt, Gisela and Dillon, Paul},
  title = {Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment},
  journal = {PharmacoEconomics - Open},
  year = {2024},
  volume = {8},
  number = {5},
  pages = {665--678},
  doi = {10.1007/s41669-024-00501-x}
}
Kostenlos starten →